<;P>;PROBLEM TO BE SOLVED: To provide an HLA-A2 restrictive antigen peptide. <;P>;SOLUTION: Provided is the HLA-A2 restrictive antigen peptide originated from Aurora-A and comprising an amino acid sequence of YLILEYAPL. An Aurora-A specific CD8+T-cell activated with the antigen peptide recognizes the antigen peptide bound HLA-A2 molecule on cells, exhibits cytotoxicity, and can attack malignant tumor cells expressing Aurora-A. The peptide is useful in a medical treatment field for malignant tumors, such as cell immunotherapy or vaccine therapy. <;P>;COPYRIGHT: (C)2009,JPO&INPIT